ESR1 and breast carcinoma: Among these registered cases, which likely encompasses all Japanese patients with breast cancer who received surgery or initiated treatment in 2018, 53,833 (56.7%) had ER+/HER2- breast cancer (ER and/or HER2 expression data were missing for 24.3% of patients) [5].